• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Palvella Therapeutics Inc.

    4/30/25 4:08:36 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PVLA alert in real time by email
    DEFA14A 1 tm2512493d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

     

    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:
    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material under §240.14a-12

     

     

    PALVELLA THERAPEUTICS, INC.

    (Name of Registrant as specified in its Charter)

     

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

     

    Payment of Filing Fee (Check all boxes that apply):
    x No fee required
    ¨ Fee paid previously with preliminary materials
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

    GRAPHIC

    www.investorvote.com/PVLA Step 1: Go to www.investorvote.com/PVLA. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/PVLA or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 0451XC Important Notice Regarding the Availability of Proxy Materials for the Palvella Therapeutics, Inc. Stockholder Meeting to be Held on June 10, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and 10-K for fiscal year end December 31, 2024 are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 30, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/PVLA. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Palvella Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 30, 2025. Palvella Therapeutics, Inc. Annual Meeting of Stockholder will be held on June 10, 2025 virtually via the internet at https://meetnow.global/MLTSDDP at 11:00 a.m. EST. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3: 1. Election of two director nominees to serve as Class II directors whose term will expire in 2028: 01 - Elaine J. Heron, PhD 02 - Tadd S. Wessel 2. Ratification of the appointment of Ernst & Young as the Company’s independent registered public accounting firm for the 2025 fiscal year. 3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Stockholder Meeting Notice

    Get the next $PVLA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PVLA

    DatePrice TargetRatingAnalyst
    8/6/2025$54.00Outperform
    Raymond James
    7/21/2025$56.00Buy
    Truist
    4/9/2025$50.00Buy
    Chardan Capital Markets
    3/26/2025$45.00Buy
    Stifel
    3/7/2025$50.00Sector Outperform
    Scotiabank
    2/20/2025$39.00Buy
    Canaccord Genuity
    2/5/2025$44.00Buy
    TD Cowen
    12/26/2024$38.00Buy
    H.C. Wainwright
    More analyst ratings

    $PVLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wessel Tadd S.

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 8:00:08 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiritsy Christopher P

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:56 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jenkins George M

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:46 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ p

    8/14/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

    WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events

    8/7/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

    WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palve

    8/5/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $51,720 worth of shares (4,000 units at $12.93), increasing direct ownership by 2% to 180,671 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    12/19/24 10:23:28 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    SEC Filings

    View All

    SEC Form 10-Q filed by Palvella Therapeutics Inc.

    10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    8/14/25 8:00:14 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    8/14/25 7:30:14 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    6/11/25 4:05:57 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Palvella Therapeutics with a new price target

    Raymond James initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $54.00

    8/6/25 8:01:45 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Palvella Therapeutics with a new price target

    Truist initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $56.00

    7/21/25 8:38:19 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Palvella Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $50.00

    4/9/25 7:50:47 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Financials

    Live finance-specific insights

    View All

    Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ p

    8/14/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

    WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events

    8/7/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of Ma

    5/15/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

    Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

    5/27/25 8:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care